D
Darja Schmidt
Publications - 14
Citations - 414
Darja Schmidt is an academic researcher. The author has contributed to research in topics: Vaccination & Medicine. The author has an hindex of 6, co-authored 7 publications receiving 151 citations.
Papers
More filters
Journal ArticleDOI
Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox
Phillip R. Pittman,Matthew Hahn,HeeChoon S. Lee,Craig D. Koca,Nathaly Samy,Darja Schmidt,Joachim Hornung,Heinz Weidenthaler,Christopher R. Heery,Thomas Meyer,Günter Silbernagl,Jane Maclennan,Paul Chaplin +12 more
TL;DR: Immune responses and attenuation of the major cutaneous reaction suggest that this modified vaccinia Ankara (MVA) vaccine protected against variola infection.
Journal ArticleDOI
A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis
Richard N. Greenberg,Yadira M Hurley,Dinh V. Dinh,Serena Mraz,Javier Gómez Vera,Dorothea von Bredow,Alfred von Krempelhuber,Siegfried Roesch,Garth Virgin,Nathaly Arndtz-Wiedemann,Thomas Meyer,Darja Schmidt,Richard A. Nichols,Philip M. Young,Paul Chaplin +14 more
TL;DR: MVA has a favorable safety profile and the ability to elicit vaccinia-specific immune responses in subjects with AD and the size of the study population limited the detection of serious adverse events occurring at a frequency less than 1%.
Journal ArticleDOI
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.
Richard N. Greenberg,Christine M. Hay,Jack T. Stapleton,Thomas C. Marbury,Eva Wagner,Eva Kreitmeir,Siegfried Roesch,Alfred von Krempelhuber,Philip M. Young,Richard A. Nichols,Thomas Meyer,Darja Schmidt,Josef Weigl,Garth Virgin,Nathaly Arndtz-Wiedemann,Paul Chaplin +15 more
TL;DR: The results suggest that a single dose of MVA in a 56–80 years old population was well tolerated and sufficient to rapidly boost the long-term B cell memory response induced by a prior vaccination with a traditional smallpox vaccine.
Journal ArticleDOI
A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS
Edgar T. Overton,Steven J. Lawrence,Jack T. Stapleton,Heinz Weidenthaler,Darja Schmidt,Brigitte Koenen,Günter Silbernagl,Katrin Nopora,Paul Chaplin +8 more
TL;DR: 3 MVA-BN dosing regimens were evaluated for safety, tolerability, and immunogenicity in persons with HIV (PWH) who had a history of AIDS and, based on the immune response previously reported for healthy participants, a third dose (booster) does not appear necessary, even for immunocompromised participants.
Journal ArticleDOI
Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A randomized phase I clinical trial
Nathaly Samy,Daniela Reichhardt,Darja Schmidt,Liddy M Chen,Günter Silbernagl,Sanja Vidojkovic,Thomas Ph Meyer,Elke Jordan,Tatiana Adams,Heinz Weidenthaler,Daria Stroukova,Sonja De Carli,Paul Chaplin +12 more
TL;DR: It is demonstrated that the well tolerated MVA-BN-RSV vaccine candidate induces broad cellular and humoral immune responses, warranting further development.